Drug Approval | December 14, 2024
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Final decision from the European Commission is anticipated within the coming months
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Decision on EU marketing authorisation for this population expected by September 2024
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Subscribe To Our Newsletter & Stay Updated
